Efficacy of terpenoids in attenuating pulmonary edema in acute lung injury: A meta-analysis of animal studies

Shuai Wang¹, Sean X. Luo¹, Jing Jie², Dan Li², Han Liu²* and Lei Song²*

¹Department of Vascular Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, JL, China, ²Center for Pathogen Biology and Infectious Diseases, Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Department of Respiratory Medicine, State Key Laboratory for Zoonotic Diseases, The First Hospital of Jilin University, Changchun, China

Background: The clinical efficiency of terpenoids in treating human acute lung injury (ALI) is yet to be determined. The lipopolysaccharide-induced rat model of ALI is a well-established and widely used experimental model for studying terpenoids’ effects on ALI. Using a systematic review and meta-analysis, the therapeutic efficiency of terpenoid administration on the lung wet-to-dry weight ratio in rats was investigated.

Methods: Using the Cochrane Library, Embase, and PubMed databases, a comprehensive literature search for studies evaluating the therapeutic efficiency of terpenoids on ALI in rats was conducted. The lung wet-to-dry weight ratio was extracted as the main outcome. The quality of the included studies was assessed using the Systematic Review Center for Laboratory Animal Experimentation’s risk of bias tool.

Results: In total, 16 studies were included in this meta-analysis. In general, terpenoids significantly lowered the lung wet-to-dry weight ratio when compared with the control vehicle ($p = 0.0002$; standardized mean difference (SMD): $-0.16$, 95% confidence interval (CI): $-0.24$, $-0.08$). Subgroup analysis revealed that low dose ($\leq 10 \mu$mol/kg) ($p < 0.0001$; SMD: $-0.68$, 95% CI: $-1.02$, $-0.34$), intraperitoneal injection ($p = 0.0002$; SMD: $-0.43$, 95% CI: $-0.66$, $-0.20$), diterpenoid ($p = 0.004$; SMD: $-0.13$, 95% CI: $-0.23$, $-0.04$), and triterpenoid ($p = 0.04$; SMD: $-0.28$, 95% CI: $-0.54$, $-0.01$) significantly lowered the lung wet-to-dry weight ratio when compared with the control vehicle.

Conclusion: A low dose of diterpenoid and triterpenoid administered intraperitoneally is effective in alleviating ALI. This systematic review and meta-analysis provides a valuable mirror for clinical research aiming at the advancement of terpenoids for preventive and therapeutic use.

Systematic Review Registration: CRD42022326779
Introduction

Acute lung injury (ALI) is an acute inflammatory disease that disrupts the lung's endothelial and epithelial barriers (Manicone, 2009). It is associated with systemic inflammatory response syndrome and multiple organ dysfunction syndrome (Wu et al., 2021). ALI, which is characterized by pulmonary edema and severe hypoxia, has also been regarded as the leading cause of death in patients with sepsis, imposing an enormous health burden worldwide each year (Schingnitz et al., 2010).

Although the pathophysiology of ALI has been extensively studied, effective clinical treatments for ALI remain limited. Therefore, there is an urgent need for the development of additional medications to treat ALI. Several natural compounds, such as terpenoids, alkaloids, and flavonoids, have been used over the last few years to treat ALI (Ren et al., 2019; Zhang et al., 2019; Zhao et al., 2021). Terpenoids, also known as isoprenoids, are the most abundant and structurally diverse natural compounds found in numerous plant species. They are a diverse and large group of naturally occurring organic chemicals derived from the 5-carbon compound isoprene. In addition, they are known to have diverse pharmacological properties, including antiatherosclerotic, antitumor, anti-inflammatory, antinociceptive, and antimarialar activities (Liu et al., 2019; Yuan et al., 2020; El-Baba et al., 2021; Sankhuan et al., 2022). The majority of research on terpenoids’ anti-ALI effects has focused on diterpenoids; however, there is no consensus on other terpenoids (Yang et al., 2011; Yang et al., 2014; Li et al., 2018a).

Endotoxin can enter humans’ airways through inhalation of contaminated dust or aerosol particles in hospital, occupational, agricultural, and domestic environments. Lipopolysaccharide (LPS), which is a major endotoxin component of Gram-negative bacteria, is regarded as the most important pathogen responsible for the development of ALI in sepsis (Li et al., 2014a; Park et al., 2018). Animal studies allow for the investigation of the efficacy and safety of novel therapies, linking basic research and clinical trials. LPS is thought to be a significant inducer of lung injury. Because of its widespread use and accessibility, LPS-induced lung injury is the most commonly used animal model of ALI for replicating the pathophysiological process (Li et al., 2018a). In this present meta-analysis, we investigated the effects of terpenoid administration on the wet-to-dry weight (W/D) ratio of the lungs in rats with LPS-induced ALI to better understand the preventive and therapeutic potential of terpenoids on ALI.

Materials and methods

Reporting standards

The systematic review protocol for animal intervention studies was prepared in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline and the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) format (Hooijmans and Ritskes-Hoitinga, 2013; De Vries et al., 2015).

Search strategy

A comprehensive search was conducted by a competent information specialist (SW) in the Cochrane Library, Embase, and PubMed databases between January 2000 and March 2022 using the terms “acute lung injury,” “ALI,” “terpenoid,” “lipopolysaccharide,” “LPS,” and “rat.” The search terms are as follows: (acute lung injury or ALI) and (diterpenoid or hemiterpenoid or monoterpenoid or polyterpenoid or sesquiterpenoid or sesterterpenoid or terpenoid or tetraterpenoid or triterpenoid) and (lipopolysaccharide or LPS) and (rat or rats). Following a manual screening, further relevant studies were identified from the datasheet of included and reviewed articles.

Inclusion and exclusion criteria

The inclusion criteria are as follows: (a) original research, (b) terpenoid intervention, and (c) rat with LPS-induced ALI research model. The exclusion criteria were as follows: (a) reviews, abstracts, case reports, comments, and editorials; (b) missing data; (c) duplicate and/or overlapping datasets; and (d) publications that were not written in English.

Study selection

To collect qualified studies, the abstracts and titles of the articles identified by the comprehensive search were independently reviewed by three investigators (SW, JJ, and HL). The full text of potentially eligible studies was thereafter reviewed and checked by three investigators (SL, DL, and LS) to determine if the studies met the inclusion and exclusion criteria. Disagreements as regards the study’s selection were resolved through discussion and compromise.
Data extraction

The characteristic data were extracted from qualified studies independently by three investigators (SL, LS, and HL), such as publication year, first author name, sample size of control and terpenoid groups, age, gender, rat strain and weight, diet type, terpenoid dosage, the interval between LPS administration and sacrifice, route and duration of LPS and terpenoid administration, lung wet-to-dry weight ratio, and dryer parameter. The statistics displayed graphically in the original publications were extracted using Adobe Photoshop (Ps v7.0). The main outcome was the lung wet-to-dry weight ratio, which is measured as a numerical value. Disagreements as regards data extraction were resolved through discussion and compromise.

Quality assessment

The quality of the included studies was assessed by two investigators (SW and JJ) using SYRCLE’s risk of bias tool. The allocation concealment, incomplete outcome data, randomization, blinding and selective outcome assessments, baseline characteristics, random housing, domains evaluating sequence generation, and other sources of bias were included in the SYRCLE’s risk of bias tool (Hooijmans et al., 2014). Publication bias was assessed through visual inspection of funnel plots. Disagreements about quality assessment were resolved through discussion and compromise.

Data synthesis and statistical analysis

All statistical analyses were conducted using the Review Manager (RevMan v5.3) software. The effects of control vehicle and terpenoids on lung wet-to-dry weight ratio were assessed using the mean differences with 95% confidence intervals (CI). A fixed effects model was used to pool studies, and the inconsistency index was used to calculate heterogeneity as high ($I^2 \geq 50\%$) or moderate ($I^2 \geq 30\%$).

In one study, datasets with more than three independent groups, namely, a control group, a low terpenoid dosage group, and a high terpenoid dosage group, were defined. A single control group was compared with various groups that investigated different terpenoid dosages in eight studies (Yang et al., 2011; Chen et al., 2014; Yang et al., 2014; Wei and Wang, 2017; Li et al., 2018a; Ren et al., 2019; Wang et al., 2021; Wu et al., 2021). To avoid a redundant expansion in the meta-analysis sample size, the number of samples in the control group in each study was divided by those in the matched groups. Subanalyses of the effects of different terpenoid routes and doses on lung wet-to-dry weight ratio were conducted. A sensitivity analysis was conducted to assess the robustness of the results. A $p$-value of $<0.05$ was considered statistically significant.
| Study          | Terpenoid          | Gender | Age | Strain      | Weight | Route of LPS | Dose of LPS | Dose of terpenoid | Interval between LPS administration and sacrifice | Route of terpenoid | Parameter of dryer | Groups and sample size |
|---------------|--------------------|--------|-----|-------------|--------|--------------|-------------|-------------------|-------------------------------------------------|-------------------|---------------------|----------------------|
| Ali F, 2021   | Aescin, triterpenoid | Male   | 8 w | Wistar      | 180–200 g | i.t.         | 8 mg/kg     | 4.42 µmol/kg      | 24 h                                            | i.g.              | 80°C                 | Control = 10         |
| Chen J, 2014  | Triptolid, diterpenoid | Male   | ?   | Sprague Dawley | 200–250 g | i.v.         | 5 mg/kg     | 0.28 µmol/kg      | 12 h                                            | i.p.              |                     | Control = 5          |
| Dikmen N, 2021| Oleuropein, monoterpenoid | Male   | 8–10 w | Wistar  | 180–250 g | i.t.         | 5 mg/kg     | 370 µmol/kg       | 20 h                                            | i.g.              | 60°C                 | Control = 8          |
| Li J, 2017    | Tanshinone IIA, diterpenoid | Male   | 10 w | Wistar      | 250–300 g | i.v.         | 5 mg/kg     | 17 µmol/kg        | 48 h                                            | i.v.              |                     | Diterpenoid high = 24 |
| Li L, 2018    | Tanshinone IIA, diterpenoid | Male   | 8 w  | Sprague Dawley | 200–220 g | i.p.         | 10 mg/kg    | 1 µmol/kg         | 8 d                                             | i.p.              |                     | Diterpenoid medium = 15 |
| Li S, 2021    | Retinoic acid, diterpenoid | Male   | 8–10 w | Sprague Dawley | 220–270 g | i.v.         | 5 mg/kg     | 22 µmol/kg        | 12 h                                            | i.t.              | 80°C                 | Control = 10          |
| Luo X, 2019   | Genipin, monoterpenoid | Male   | 8 w  | Sprague Dawley | 180–220 g | i.t.         | 5 mg/kg     | 17 µmol/kg        | 6 h                                             | i.p.              | 80°C                 | Control = 8          |
| Shi XM, 2007  | Tanshinone IIA, diterpenoid | ?      | ?   | Sprague Dawley | 240–280 g | i.v.         | 5 mg/kg     | 17 µmol/kg        | 6 h                                             | i.p.              | 80°C                 | Control = 8          |
| Wang YJ, 2020 | Zaluzanin D, sesquiterpenoid | Male   | 6–8 w | Sprague Dawley | ?         | i.t.         | 3 mg/kg     | 7 d                                            | i.v.              | 60°C                 | Sesquiterpenoid high = 6 |

(Continued on following page)
| Study                  | Terpenoid                      | Gender | Age | Strain       | Weight    | Route of LPS | Dose of LPS | Dose of terpenoid | Interval between LPS administration and sacrifice | Route of terpenoid | Parameter of dryer | Groups and sample size |
|-----------------------|--------------------------------|--------|-----|--------------|-----------|--------------|-------------|-------------------|------------------------------------------------|-------------------|----------------------|------------------------|
| Wei Y, 2017 (Wei and Wang, 2017) | Celastrol, triterpenoid       | Male   | ?   | Wistar       | 180–220 g | i.t.          | 2 mg/kg     | 69 µmol/kg        | 24 h                                            | i.g.               | 80°C                 | Control = 8             |
| Wu Y, 2021 (Wu et al., 2021)   | Platycodin D, triterpenoid    | ?      | 6 w | Sprague Dawley | 90–110 g  | i.t.          | 5 mg/kg     | 1.1 µmol/kg       | ?                                               | i.p.               | 60°C                 | Triterpenoid high = 7  |
| Yang N, 2014 (Yang et al., 2014) | Andrographolide, diterpenoid  | Male   | 8 w | Sprague Dawley | 180–220 g | i.v.          | 5 mg/kg     | 128 µmol/kg       | 6 h                                             | i.g.               | 80°C                 | Diterpenoid high = 43 |
| Yang W, 2011 (Yang et al., 2011) | Isoforskolin, diterpenoid     | Male   | 12 w| Sprague Dawley | 260–300 g | i.v.          | 6 mg/kg     | 49 µmol/kg        | 3 h                                             | i.p.               | 80°C                 | Diterpenoid low = 43   |
| Yuan Q, 2014 (Yuan et al., 2014) | Ginsenoside Rh1, triterpenoid | Male   | ?   | Wistar       | 300–350 g | i.v.          | 0.1 mg/kg   | 12 µmol/kg        | ?                                               | i.v.               | 80°C                 | Control = 10            |
| Zhang J, 2020 (Zhang et al., 2020) | Artesunate, sesquiterpenoid  | ?      | ?   | Sprague Dawley | 220–250 g | i.t.          | 5 mg/kg     | 5.2 µmol/kg       | 24 h                                            | i.p.               | ?                    | Control = 8             |
| Zhang Z, 2019 (Zhang et al., 2019) | Genipin, monoterpenoid       | Male   | 8 w | Sprague Dawley | 180–220 g | i.t.          | 5 mg/kg     | 22 µmol/kg        | 12 h                                            | i.p.               | 80°C                 | Monoterpenoid high = 6 |

Note: i.v., intravenous injection; i.t., intratracheal administration; i.p., intraperitoneal injection; i.g., intragastric administration; ? = not reported.
Results

Study selection

Through the search strategy, 872 articles were identified. The investigators extracted the abstracts and titles and identified 38 studies that met the inclusion criteria. After reviewing all of the publications, 10 studies were excluded because of missing outcome data (Ehrhart et al., 2000; Tawadros et al., 2007; Nader and Baraka, 2012; An et al., 2014; Wang et al., 2015; Liu and Chen, 2016; Shen et al., 2017; Ni et al., 2019; Wang et al., 2019; Yang et al., 2019), and another 12 studies were excluded because multiple interventions were investigated (Murakami et al., 2000; Lin et al., 2011; Li et al., 2014b; Li et al., 2016a; Li et al., 2016b; Baradaran Rahimi et al., 2019; Ye et al., 2019; Duan et al., 2020; Yue et al., 2020; Choi et al., 2021; Zhang et al., 2021; Liu et al., 2022). In conclusion, 16 studies were included in this meta-analysis, as described below (Shi et al., 2007; Yang et al., 2011; Chen et al., 2014; Yang et al., 2014; Yuan et al., 2014; Wei and Wang, 2017; Li et al., 2018a; Li et al., 2018b; Luo et al., 2019; Ren et al., 2019; Zhang et al., 2020; Ali et al., 2021; Dikmen et al., 2021; Li et al., 2021; Wang et al., 2021; Wu et al., 2021) (Figure 1).

Study characteristics

From the 16 included studies, 29 datasets and 499 rats were extracted. The characteristics of these studies are shown in Table 1. Rats ranged in age from 6 to 8 weeks and in weight from 90 to 350 g. In terms of intervention, diterpenoid, monoterpenoid, sesquiterpenoid, and triterpenoid were used in seven studies (Shi et al., 2007; Yang et al., 2011; Yang et al., 2014; Wei and Wang, 2017; Li et al., 2018a; Li et al., 2018b; Luo et al., 2019), three studies (Yuan et al., 2014; Ren et al., 2019; Zhang et al., 2020; Ali et al., 2021; Dikmen et al., 2021; Li et al., 2021; Wang et al., 2021; Wu et al., 2021), and intratracheally in eight studies (Chen et al., 2014; Yang et al., 2014; Yuan et al., 2014; Wei and Wang, 2017; Li et al., 2018a; Li et al., 2018b; Luo et al., 2019; Ren et al., 2019; Ali et al., 2021; Wu et al., 2021), and intratracheally in one study (Li et al., 2021). The terpenoid dosage ranged from 0.08 to 370 μmol/kg. The terpenoid was given prior to LPS in eight studies (Chen et al., 2014; Yang et al., 2014; Yuan et al., 2014; Li et al., 2018a; Luo et al., 2019; Ren et al., 2019; Zhang et al., 2020; Li et al., 2021), after LPS in seven studies (Shi et al., 2007; Yang et al., 2011; Wei and Wang, 2017; Li et al., 2018b; Ali et al., 2021; Dikmen et al., 2021; Wang et al., 2021), and undetermined in one study (Wu et al., 2021). The interval between LPS administration and sacrifice ranged from 3 h to 8 days. The drying time ranged from 20 to 72 h, and the temperature ranged from 60 to 80°C.

Quality assessment

The quality assessment of these studies is shown in Figure 2. In total, 12 studies were randomized, with eight studies demonstrating unclear risks of bias in blinding and allocation concealment. All studies’ outcomes were reported, with six studies demonstrating an unclear risk of selective outcome reporting. Overall, the risk of bias from other sources was low. The potential publication bias was evaluated through visual inspection of a funnel plot (Figure 3).

Effect of terpenoids on lung wet-to-dry weight ratio

The effect of terpenoids on lung wet-to-dry weight ratio was presented for 29 datasets acquired from 16 studies (rats given terpenoids [n = 317] vs. rats given a control vehicle [n = 182]). Overall, terpenoids significantly reduced the lung wet-to-dry weight ratio when compared with the control vehicle (p = 0.0002; standardized mean difference (SMD): −0.16; 95% CI: −0.24, −0.08), with no evidence of heterogeneity among studies (F = 0%) (Figure 4).

Subgroup analyses were conducted to assess the effects of diterpenoid, monoterpenoid, sesquiterpenoid, and triterpenoid on the lung wet-to-dry weight ratio. Monoterpenoid (rats given a monoterpenoid [n = 26] vs. rats given a control vehicle [n = 20]; p = 0.22; SMD: −0.21; 95% CI: −0.55, 0.13) and sesquiterpenoid (rats given a sesquiterpenoid [n = 26] vs. rats given a control vehicle [n = 14]; p = 0.22; SMD: −0.26; 95% CI: −0.69, 0.16) did not significantly lower the lung wet-to-dry weight ratio when
compared with the control vehicle, with no evidence of heterogeneity among studies ($I^2 = 0\%$). Diterpenoid (rats given a diterpenoid [$n = 207$] vs. rats given a control vehicle [$n = 111$]) significantly reduced the lung wet-to-dry weight ratio when compared with the control vehicle ($p = 0.004; \text{SMD: } -0.13; 95\% \text{ CI: } -0.23, -0.04$), with evidence of low heterogeneity among studies ($I^2 = 20\%$). Triterpenoid (rats given a triterpenoid [$n = 58$] vs. rats given a control vehicle [$n = 37$]) significantly decreased the lung wet-to-dry weight ratio when compared with the control vehicle ($p = 0.04; \text{SMD: } -0.28; 95\% \text{ CI: } -0.54, -0.01$), with no evidence of heterogeneity among studies ($I^2 = 0\%$) (Figure 4). The sensitivity analysis, which substituted the random effects model for the fixed effects model, had no effect on the overall outcome ($\text{SMD: } -0.16, \text{ CI: } -0.24, -0.08 \text{ vs. SMD: } -0.36, \text{ CI: } -0.55, -0.17$).

In terms of the administration route, subgroup analyses revealed that intraperitoneal injection of terpenoid (rats given...
a terpenoid \(n = 81\) vs. rats given a control vehicle \(n = 51\) significantly reduced the lung wet-to-dry weight ratio when compared with the control vehicle \((p = 0.0002; \text{SMD: } -0.43; 95\% \text{ CI: } -0.66, -0.20)\), with no evidence of heterogeneity among studies \((I^2 = 0\%)\). However, intravenous injection of terpenoid (rats given a terpenoid \(n = 64\) vs. rats given a control vehicle \(n = 34\)) did not significantly lower the lung wet-to-dry weight ratio when compared with the control vehicle \((p = 0.25; \text{SMD: } -0.12; 95\% \text{ CI: } -0.32, -0.08)\), with no evidence of heterogeneity among studies \((I^2 = 0\%)\). Likewise, intragastric administration of terpenoid (rats given a terpenoid \(n = 96\) vs. rats given a control vehicle \(n = 54\)) did not significantly lower the lung wet-to-dry weight ratio when compared with the control vehicle \((p = 0.06; \text{SMD: } -0.10; 95\% \text{ CI: } -0.20, -0.00)\), with no evidence of heterogeneity among studies \((I^2 = 0\%)\) (Figure 5). The sensitivity analysis, which substituted the random effects model for the fixed effects model, had no effect on the overall outcome \((\text{SMD: } -0.15, 95\% \text{ CI: } -0.24, -0.06; \text{SMD: } -0.36, 95\% \text{ CI: } -0.57, -0.15)\).

In terms of terpenoid dosage, subgroup analyses revealed that low doses of terpenoid administered intraperitoneally (rats given terpenoid at a dose of 10 μmol/kg or lower \(n = 32\)) vs. rats given a control vehicle \((n = 20)\) significantly lowered the lung wet-to-dry weight ratio when compared with the control vehicle \((p < 0.0001; \text{SMD: } -0.68; 95\% \text{ CI: } -1.02, -0.34)\), with no evidence of heterogeneity among studies \((I^2 = 0\%)\). However, the high dose (rats given terpenoid at a dose greater than 10 μmol/kg \(n = 49\) vs. rats given a control vehicle \(n = 31)\) did not
significantly lower the lung wet-to-dry weight ratio when compared with the control vehicle (p = 0.16; SMD: −0.22; 95% CI: −0.54, −0.09), with no evidence of heterogeneity among studies (I² = 0%) (Figure 6). The sensitivity analysis, which substituted the random effects model for the fixed effects model, had no effect on the overall outcome (SMD: −0.43, CI: −0.66, −0.20 vs. SMD: −0.46, CI: −0.83, −0.09).

**Discussion**

Despite significant advances in pharmacotherapy agents for ALI, such as antibiotics, N-acetylcysteine, β-agonists, corticosteroids, surfactants, and statins, an efficient approach to lowering ALI morbidity and mortality is yet to be identified (Lewis et al., 2019). Because diterpenoids were found to be promising in treating ALI in some studies (Yang et al., 2011; Yang et al., 2014; Li et al., 2018a), it was necessary to investigate the pharmacological effects of terpenoids on ALI. The use of animal models provides a valuable gateway for preclinical research, identifying novel therapeutic strategies for disease and developing new drugs. An ideal animal model should be able to replicate the consequences and mechanisms of human disease, including pathological and physiological hallmarks. LPS is a component of Gram-negative bacterial cell walls. LPS-induced animal models, by inhalation or systemic (intravenous and intraperitoneal) administration, reproduce acute damage to the lung epithelial and endothelial barriers, as well as acute inflammatory responses, in a short period of time (typically <48 h) (Matute-Bello et al., 2008). LPS-induced injury is a valuable in vivo experimental model that is similar to ALI and acute respiratory distress syndrome in humans. LPS is easy to use, and its outcomes are often replicable in experiments. Although mouse models of human disease are widely used because of the availability of specific reagents and the development of transgenic mice that can be administered to assess the physiological function of specific genes, animal size remains an important consideration when choosing an animal model for ALI. Because there is no difference between rats and mice in ALI animal models (Matute-Bello et al., 2008), rats were used as experimental animals in this study.
Previous animal experiments suggest that natural terpenoids may have therapeutic effects on ALI. However, study parameters such as sample size, animal strain and age, and treatment and follow-up duration were noted to differ among studies. A quantitative and comprehensive analysis of these heterogeneous sources of animal model data can provide insights into the benefits of terpenoids in the treatment of ALI. Therefore, we conducted a systematic review and meta-analysis to investigate the effects of terpenoids on lung wet-to-dry weight ratio in rats with LPS-induced ALI. The findings revealed that the use of terpenoids significantly reduced the lung wet-to-dry weight ratio and alleviated pulmonary edema when compared with the control group.

The terpenoid family includes monoterpenoid, sesquiterpenoid, diterpenoid, triterpenoid, and tetraterpenoid (Christianson, 2017). In a subgroup analysis, the number of isoprene groups, monoterpenoid and sesquiterpenoid, did not drastically lower the lung wet-to-dry weight ratio. By contrast, diterpenoid and triterpenoid attenuated pulmonary edema and ameliorated ALI in LPS-induced ALI rats compared with the control vehicle. We presumed that the differences among the groups might be induced by the sample size gap and underlying publication bias. Of course, more studies are needed to confirm this speculation. Moreover, a low dose (≤10 µmol/kg) of diterpenoid and triterpenoid via intraperitoneal injection showed a significant outcome for decreasing lung wet-to-dry weight ratio. To our knowledge, this meta-analysis is an initial assessment of the therapeutic efficiency of terpenoids on LPS-induced ALI in rats. The total outcomes might offer a valuable reference to the future preventive and therapeutic use of terpenoids in human ALI.

In the overall analysis, there was no heterogeneity among studies. However, among studies in the subgroups of diterpenoid and low-dose terpenoid, it had a low degree of heterogeneity. Possible origin of heterogeneity contained strain of rat, route of LPS, and interval between LPS administration and sacrifice, each of which can influence the progression of ALI (Chen et al., 2010). The meta-analysis is coupled with some restrictions. First, the correlation between the outcomes and humans is restrained by the differences between species in the development of pulmonary edema. The LPS-induced ALI animal model is well reputable, and the main characteristics and development of pulmonary edema in humans and rats emerge similar, but to a certain extent, it is different in pathogenesis (Tomashefski, 2000). We realize that an LPS-induced ALI animal model duplicates a lot of pathological features, but it is still relatively simple and rapid to reproduce the pathologic processes of humans (Matute-Bello et al., 2008). Second, other animal models of ALI were not included in this meta-analysis, such as pigs and sheep, which are easier to be induced by LPS because they have a more sensitive pulmonary hypertensive response and a higher speed circulation than rats (Warner et al., 1988; Schmidhammer et al., 2006). Third, only the lung wet-to-dry weight ratio was extracted to investigate the effects of terpenoids on ALI. Other parameters, such as proinflammatory cytokines, including tumor necrosis factor and interleukin, lung injury score, and lung-to-body weight ratio, were not considered (Eastwood et al., 2015; Butt et al., 2016). Fourth, hemiterpenoids, sesterterpenoids, and other terpenoids were not investigated in the analysis. In addition,

![FIGURE 6](https://doi.org/10.3389/fphar.2022.946554)

The forest plot of therapeutic efficiency of terpenoid dose on lung wet-to-dry weight ratio. Subgroup analyses investigated therapeutic efficiency of high dose (>10 µmol/kg) and low dose (≤10 µmol/kg). CI, confidence interval; IV, inverse variance; Std, standard; SD, standard deviation.
more studies based on a huge number of samples and large-scale animal models are still necessary for determining whether terpenoids are effective for attenuating ALI in humans.

This meta-analysis showed that terpenoid is beneficial for alleviating ALI in rats. In particular, low-dose (≤10 µmol/kg) diterpenoid and triterpenoid significantly decrease lung wet-to-dry weight ratio in rats via intraperitoneal injection. We need more well-designed, prospective, and extensive animal model research to expand our understanding of the mechanisms of terpenoids in ALI treatment. We still need randomized controlled trials in humans to demonstrate the clinical benefit of terpenoids in the prevention and therapy of ALI.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material; further inquiries can be directed to the corresponding authors.

Author contributions

SW conducted the analysis, JJ and DL collected and performed a preliminary analysis of references, HL and SL wrote the manuscript, and LS designed and revised the manuscript.

References

Ali, F. E. M., Ahmed, S. F., Eltawwily, A. H., Yousef, R. S., Ali, H. S., Mahmoud, A. R., et al. (2021). Pretreatment with coenzyme Q10 combined with aescin protects against sepsis-induced acute lung injury. Cell Tissues Organs 210 (3), 195–217. doi:10.1159/000516192

An, J. F., Sun, Y., Zhang, Q. L., Zhang, F. L., and Zhang, J. L. (2014). The effects of germacrene on lipopolysaccharide-induced acute lung injury in neonatal rats. Cell Mol. Biol. (Noisy-le-grand) 60 (4), 8–12.

Baradaran Rahimi, V., Rahshahande, H., Raucci, F., Ruso, B., Shirzazinia, R., Samzadeh Kermani, A., et al. (2019). Anti-inflammatory and anti-oxidant activity of portulaca oleracea extract on LPS-induced rat lung injury. Molecules 24 (1), 139. doi:10.3390/molecules24010139

Butt, Y., Kurdowska, A., and Allen, T. C. (2016). Acute lung injury: A clinical and molecular review. Arch. Pathol. Lab. Med. 140 (4), 345–350. doi:10.5858/arpa.2015-0519-RA

Chen, H., Bai, C., and Wang, X. (2010). The value of the lipopolysaccharide-induced acute lung injury model in respiratory medicine. Expert Rev. Respir. Med. 4 (6), 773–783. doi:10.1586/ers.10.71

Chen, J., Guo, J., Yang, J., Zhang, Y., and Wang, L. (2014). Effect of triptolide on the regulation of ATP-binding cassette transporter A1 expression in lipopolysaccharide-induced acute lung injury of rats. Mol. Med. Rep. 10 (6), 3015–3020. doi:10.3892/mmr.2014.2636

Choi, M., Thi, L. T., Lee, Y., Piao, C., Choi, J. S., and Lee, M. (2021). Dual-functional dendrimer micelles with glycyrrhizic acid for anti-inflammatory therapy of acute lung injury. ACS Appl. Mater Interfaces 13 (40), 47313–47326. doi:10.1021/acsami.1c08107

Christianson, D. W. (2017). Structural and chemical Biology of terpenoid cyclases. Chem. Rev. 117 (17), 11570–11648. doi:10.1021/acs.chemrev.7b00287

De Vries, R. B. M., Hooijmans, C. R., Langendam, M. W., and Luik, J. V. (2015). A protocol format for the preparation, registration and publication of systematic reviews of animal intervention studies. Evid. Based Clin. Pract. Med. 2, 1–9. doi:10.1002/ebm2.7

Dikmen, N., Cellat, M., Etyemez, M., Işler, C. T., Uyar, A., Aydn, T., et al. (2021). Amlodipine effects of olsupron on lipopolysaccharide-induced acute lung injury model in rats. Inflammation 44 (6), 2246–2259. doi:10.1007/s10575-021-01496-x

Duan, Q., Jia, Y., Qiu, Y., Jin, Y., Hu, H., and Chen, J. (2020). Narcissamine attenuates LPS-induced acute lung injury in neonatal rats through suppressing inflammation and oxidative stress. Bioengineered 11 (1), 801–810. doi:10.1080/21655979.2020.1795424

Eastwood, M. P., Russo, F. M., Toelen, J., and Deprest, J. (2015). Medical interventions to reverse pulmonary hypoplasia in the animal model of congenital diaphragmatic hernia: A systematic review. Pediatr. Pulmonol. 50 (8), 820–838. doi:10.1002/ppul.23206

Ele-Baba, C., Baasirsi, A., Kirakko, G., Dan, B., Fadlallah, S., Moodad, S., et al. (2021). Terpenoids’ anti-cancer effects: Focus on autophagy. Apoptosis 26 (9-10), 491–511. doi:10.1007/s10495-021-01684-y

Hooijmans, C. R., and Ritches-Hotinga, M. (2013). Progress in using systematic reviews of animal studies to improve translational research. PLoS Med. 10 (7), e1001482. doi:10.1371/journal.pmed.1001482

Hooijmans, C. R., Rovers, M. M., de Vries, R. B., Lenaars, M., Ritches-Hotinga, M., and Langendam, M. W. (2014). SYRCLE’s risk of bias tool for animal studies. BMC Med. Res. Methodol. 14, 43. doi:10.1186/1471-2288-14-43

Funding

This work was supported by the Office of Science and Technology in Jilin Province (No. 202102041114YY and 20210101325JC).

Acknowledgments

We would like to thank Enago Academy for the revisions to the manuscript in terms of language and grammar.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Pterostilbene 4

Wang et al. 10.3389/fphar.2022.946554

Lewis, S. R., Pritchard, M. W., Thomas, C. M., and Smith, A. F. (2019). Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database Syst. Rev. 7 (3), CD004477. doi:10.1002/14651858.CD004477.pub3

Li, G., Zhou, C. L., Zhou, Q. S., and Zou, H. D. (2016). Galantamine protects against lipopolysaccharide-induced acute lung injury in rats. Braz J. Med. Biol. Res. 49 (2), e5008. doi:10.1590/1414-431X20155008

Li, J., Zheng, Y., Li, M. X., Yang, C. W., and Liu, Y. F. (2018). Tanshinone IIa alleviates lipopolysaccharide-induced acute lung injury by downregulating TRPM7 and pro-inflammatory factors. J. Cell Mol. Med. 22 (1), 646–654. doi:10.1111/jcmm.13350

Li, K. C., Ho, Y. L., Chen, C. Y., Hsieh, W. T., Chang, Y. S., and Huang, G. J. (2016). Lobeinoline improves acute lung injury via nuclear factor-κB-signaling pathway and oxidative stress. Respir. Physiol. Neurobiol. 225, 19–30. doi:10.1016/j.resp.2015.12.003

Li, L., Zhang, Y. G., Tan, Y. F., Zhao, J. J., Zhang, H. R., and Zhao, B. (2018). Tanshinone II is a potent candidate for treatment of lipopolysaccharide-induced acute lung injury in rat model. Oncol. Lett. 15 (2), 2550–2554. doi:10.3892/ol.2017.7581

Li, S., Lei, Y., Lei, J., and Li, H. (2021). All-trans retinoic acid promotes macrophage phagocytosis and decreases inflammation via inhibiting CD14/TLR4 in acute lung injury. Mol. Med. Rep. 24 (6), 868. doi:10.3892/mmr.2021.12508

Li, L., Liu, Y., Li, G., Wang, X., Zeng, Z., Cai, S., et al. (2014). Polydatin attenuates lipopolysaccharide-induced acute lung injury in rats. Int. J. Clin. Exp. Pathol. 7, 8401–8410.

Li, W., Huang, H., Niu, X., Fan, T., Hu, L., Li, Y., et al. (2014). Tetraphydronecropsine protects rats from LPS-induced acute lung injury. Inflammation 37 (6), 2106–2115. doi:10.1007/s10753-015-9944-7

Lin, Y., Zhu, X., Yao, W. Z., and Yang, Y. L. (2011). Yohimbine protects against endotoxin-induced acute lung injury by blockade of alpha 2A adrenergic receptor in rats. Chin. Med. J. Engl. 124 (7), 1069–1074.

Liu, H., Zhang, Y., Sun, S., and Wang, S. (2019). Efficacy of terpenoid in attenuating aortic atherosclerosis in apolipoprotein-E deficient mice: A meta-analysis of animal studies. Biomed. Res. Int. 2019, 2931831. doi:10.1155/2019/2931831

Liu, P., Hao, J., Zhao, J., Zou, R., Han, J., Tian, J., et al. (2022). Integrated network Pharmacology and experimental validation approach to investigate the therapeutic effects of caspicon on lipopolysaccharide-induced acute lung injury. Mediat. Inflamm. 2022, 9727896. doi:10.1155/2022/9727896

Liu, T. Y., and Chen, S. B. (2016). Sarcandra glabra combined with lycopene attenuating aortic atherosclerosis in apolipoprotein-E deficient mice: A meta-analysis of animal studies. Biomed. Res. Int. 2019, 2931831. doi:10.1155/2019/2931831

Shen, Y. L., Shen, H. T., Su, C. H., Chen, W. Y., Huang-Liu, R., Chen, C. J., et al. (2017). Picroside II protects rat lung and A549 cell against LPS-induced inflammation by NF-κB pathway. Inflammation 40 (3), 752–761. doi:10.1007/s10753-015-0519-3

Shi, X. M., Huang, L., Xiong, S. D., and Zhong, X. Y. (2007). Protective effects of tanshinone II A on lipopolysaccharide-induced lung injury in rats. Chin. J. Integr. Med. 13 (2), 137–140. doi:10.3892/cjm.2015.125

Tawadros, P. S., Powers, K. A., Yang, I., Becker, D. A., Ginsberg, M. D., Szaszki, Z., et al. (2007). Stilbenoylurea nitro leaves oxidative stress and reduces lung injury after hemorrhagic shock/resuscitation and LPS. Antioxid. Redox Signal 9 (11), 1971–1977. doi:10.1089/ars.2007.1765

Tomasefski, J. J., Jr. (2008). Pulmonary pathology of acute respiratory distress syndrome. Clin. Chest Med. 21 (3), 435–466. doi:10.1016/j.lcl.2007.05.008

Wang, Y. M., Ji, R., Chen, W. W., Huang, S. W., Zheng, Y. J., Yang, Z. T., et al. (2019). Paclitaxel alleviated sepsis-induced acute lung injury by activating MUC1 and suppressing TLR4/NF-κB pathway. Drug Des. Devel Ther. 13, 3391–3404. doi:10.2147/DDDT.S222296

Yang, W. Y., Qiu, X. G., and Ren, H. L. (2015). Inhibition of acute lung injury by rubifloridilactone in LPS-induced rat model through suppression of inflammatory factor expression. Int. J. Clin. Exp. Pathol. 8 (12), 15954–15959.

Ye, J., Guan, M., Lu, Y., Zhang, D., Li, C., and Zhou, C. (2019). Arbutin attenuates LPS-induced acute lung injury via inhibiting CD14/TLR4 pathways. Pulm. Pharmacol. Ther. 54, 53–59. doi:10.1016/j.ppt.2018.12.001

Ye, J., Guan, M., Lu, Y., Zhang, D., Li, C., and Zhou, C. (2019). Arbutin attenuates LPS-induced lung injury via Sirt1/Nrf2/NF-κB pathway. Pulm. Pharmacol. Ther. 54, 53–59. doi:10.1016/j.ppt.2018.12.001
Yuan, H. L., Zhao, Y. L., Ding, C. F., Zhu, P. F., Jin, Q., Liu, Y. P., et al. (2020). Anti-inflammatory and antinociceptive effects of Curcuma kwangsiensis and its bioactive terpenoids in vivo and in vitro. *J. Ethnopharmacol.* 259, 112935. doi:10.1016/j.jep.2020.112935

Yuan, Q., Jiang, Y. W., Ma, T. T., Fang, Q. H., and Pan, L. (2014). Attenuating effect of Ginsenoside Rb1 on LPS-induced lung injury in rats. *J. Inflamm. (Lond)* 11 (1), 40. doi:10.1186/s12950-014-0040-5

Yue, Q., Liu, T., and Cheng, Z. (2020). Protective effect of colchicine on LPS-induced lung injury in rats via inhibition of P-38, ERK1/2, and JNK activation. *Pharmacology* 105 (11-12), 639–644. doi:10.1159/000504759

Zhang, C., Wang, X., Wang, C., He, C., Ma, Q., Li, J., et al. (2021). Qingwenzhike prescription alleviates acute lung injury induced by LPS via inhibiting TLR4/NF-κB pathway and NLRP3 inflammasome activation. *Front. Pharmacol.* 12, 790072. doi:10.3389/fphar.2021.790072

Zhang, E., Wang, J., Chen, Q., Wang, Z., Li, D., Jiang, N., et al. (2020). Artesunate ameliorates sepsis-induced acute lung injury by activating the mTOR/AKT/PI3K axis. *Gene* 759, 144969. doi:10.1016/j.gene.2020.144969

Zhao, R., Wang, B., Wang, D., Wu, B., Jia, P., and Tan, D. (2021). Oxysterol prevents lipopolysaccharide-induced acute lung injury by activating the NLRP3 inflammasome. *Oxid. Med. Cell Longev.* 2021, 6675264. doi:10.1155/2021/6675264